antihemophilic factor viii human (Hemofil M) Report issue

Biological Approved FDA
AACT ChEMBL DrugBank Drug Central MeSH PubChem

Active Ingredient History

NOW
  • Now
Factor VIII (FVIII) is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene. Defects in this gene result in hemophilia A, an X-linked coagulation disorder. Factor VIII is produced in the liver’s sinusoidal cells and endothelial cells outside the liver throughout the body. This protein circulates in the bloodstream in an inactive form, bound to another molecule called von Willebrand factor, until an injury that damages blood vessels occurs. In response to injury, coagulation factor VIII is activated and separates from von Willebrand factor. The active protein interacts with another coagulation factor called factor IX. This interaction sets off a chain of additional chemical reactions that form a blood clot.   Wikipedia

Chemistry

More Chemistry

Pharmacology

Alternative names

alphanate | antihemophilic factor | antihemophilic factor b | antihemophilic factor human | antihemophilic factor (human) | antihemophilic factor,human | antihemophilic factor, human | antihemophilic factor viii human | bioclate | coagulation factor viii | coagulation factor viii, procoagulant component (hemophilia a) protein, human | f8b protein, human | f8 protein, human | factor viii | factor viii (antihaemophilic factor) | factor viii (human) | factor viii, human | fviii protein, human | haemate p | haemate-p | helixate | hemofil | hemofil hm | hemofil m | hemophil | humafac | human coagulation factor viii | humate-p | koate-hp | kogenate | kogenate fs | kovaltry | proplex t | xyntha

Organizations (49)

Research & Development (48)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (1)


 

Hemophilia A (approved 1966)

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Blood Coagulation Disorders (Phase 4)

Blood Loss, Surgical (Phase 2)

Blood Platelet Disorders (Phase 4)

General Surgery (Phase 3)

Healthy Volunteers (Phase 1)

Hematologic Diseases (Phase 4)

Hemophilia A (Phase 4)

Hemophilia B (Phase 4)

Pharmacokinetics (Phase 4)

von Willebrand Diseases (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 72
  • # of Trial Organizations: 48

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue